Flagship Pioneering, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001400240
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2024 · 5 positions · Total reported value $334.22M · Top-10 concentration 100.0% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 0.0% · 0 new · 0 cut · 0 exited
Active Share (vs S&P 500): 99.9% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q4 2024 13F filing, Flagship Pioneering, LLC disclosed 5 equity positions with a combined reported value of $334.22M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / Buy & Hold.
The largest disclosed positions as of Q4 2024 were MRNA ($192.60M), FHTX ($59.82M), SANA ($40.75M). By sector, the heaviest allocations are Health Care 93.5%, Other 6.5%.
Versus the prior quarter, Flagship Pioneering, LLC opened 0 new positions, trimmed 0 and fully exited 0, a turnover rate of 0.0% of positions. The portfolio's overlap with the prior quarter was 83% of names.
Of the 1 positions fully exited versus the prior quarter, the largest were SYRS ($2.78M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2024)
No new positions this quarter.
Fully Exited (vs previous quarter)
- SYRS SYROS PHARMACEUTICALS INC · prev qtr: $2.78M
Insider Transactions (Form 4)
Latest Flagship Pioneering, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Flagship Pioneering, LLC is an SEC-registered 13F filer. As of Q2 2026 it reported 5 US equity positions with a combined value of $1.54B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 5 positions · $1.54B reported value (Q2 2026)
- Top 10 holdings = 100.0% of reported value
- Largest position: GENB (GENERATE BIOMEDICINES INC) at 68.7%
- Average position size: $307.98M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
4.63M | $192.60M | 57.63% | Hold | |
| 2 |
|
12.67M | $59.82M | 17.90% | Hold | |
| 3 |
|
25.00M | $40.75M | 12.19% | Hold | |
| 4 |
|
29.23M | $21.79M | 6.52% | Hold | |
| 5 |
|
23.12M | $19.25M | 5.76% | Hold |
FAQ
What did Flagship Pioneering, LLC buy in 2024-Q4?
In its 2024-Q4 13F filing, Flagship Pioneering, LLC reported 5 equity positions worth $334.22M in aggregate; its largest disclosed positions were MRNA ($192.60M), FHTX ($59.82M), SANA ($40.75M).
How large is Flagship Pioneering, LLC's portfolio?
Flagship Pioneering, LLC reported $334.22M of long equity holdings across 5 positions as of 2024-Q4. Top-10 holdings account for 100.0% of reported value.
What is Flagship Pioneering, LLC's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / Buy & Hold, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.